Diclofenac ( DrugBank: Diclofenac )


5 diseases
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica1
34Neurofibromatosis1
46Malignant rheumatoid arthritis19
78Hypopituitarism1
271Ankylosing spondylitis6

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,340Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

34. Neurofibromatosis


Clinical trials : 133Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

46. Malignant rheumatoid arthritis


Clinical trials : 4,356Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

78. Hypopituitarism


Clinical trials : 492Drugs : 341 - (DrugBank : 47) / Drug target genes : 45 - Drug target pathways : 100 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

271. Ankylosing spondylitis


Clinical trials : 574Drugs : 359 - (DrugBank : 68) / Drug target genes : 41 - Drug target pathways : 146 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries